M&A Deal Summary

Vernalis Acquires Pragma Pharmaceuticals

On October 2, 2015, Vernalis acquired life science company Pragma Pharmaceuticals

Acquisition Highlights
  • This is Vernalis’ 1st transaction in the Life Science sector.
  • This is Vernalis’ 1st transaction in the United States.
  • This is Vernalis’ 1st transaction in New York.

M&A Deal Summary
Date 2015-10-02
Target Pragma Pharmaceuticals
Sector Life Science
Buyer(s) Vernalis
Deal Type Add-on Acquisition

Target

Pragma Pharmaceuticals

Locust Valley, New York, United States
Pragma Pharmaceuticals LLC is a pharmaceutical firm.

Search 201,292 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Vernalis

Winnersh, United Kingdom
Category Company
Founded 1988
Sector Life Science
Employees115
Revenue 21M GBP (2017)
DESCRIPTION

Vernalis Plc is a commercial stage pharmaceutical company with three marketed products; Tuzistra® XR in the US prescription cough cold market, Moxatag®, a once-a-day formulation of the antibiotic amoxicillin, also for the US prescription market, and frovatriptan an acute treatment for migraine. Vernalis Plc was founded in 1988 and is based in Winnersh, United Kingdom.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Add-on Acquisition) 1 of 1
State (New York) 1 of 1
Country (United States) 1 of 1
Year (2015) 1 of 1
Mergr

Product

Company

Legal